Comparative guide · 7 min read

EPA vs DHA vs ALA — which omega-3 do you actually need?

Updated 2026-05-02 · Reviewed by SupplementScore editors · No sponsorships

All three are "omega-3" but they're far from interchangeable. The conversion from one to another is poor in humans. Picking the right one matters more than picking a brand.

Quick verdict

Goal	Best-fit form	Why
Cardiovascular event reduction (post-MI, statin add-on)	EPA-dominant	The REDUCE-IT trial of high-dose EPA-only (icosapent ethyl, 4 g/day) showed cardiovascular event reduction. Mixed-EPA-DHA trials have been mostly null.
Pregnancy + brain development	DHA-dominant	DHA is the structural component of neural and retinal membranes. Pregnant and nursing people are usually advised 200–300 mg DHA/day minimum.
Cognitive support in older adults	DHA-leaning EPA+DHA	Mixed evidence; the strongest signals are with DHA-leaning formulations at 1+ g/day for 6+ months in apolipoprotein-E ε4 carriers.
Vegan / vegetarian general intake	Algae oil (EPA + DHA)	ALA from flax/chia is poorly converted (< 5–10% to EPA, < 1–4% to DHA). Algae oil delivers EPA and DHA directly, plant-based.

How the three differ

ALA — the plant omega-3

α-linolenic acid is found in flaxseed, chia, walnuts, and canola oil. The body can convert it to EPA and DHA — but inefficiently. In adult humans, < 5–10% of ALA is converted to EPA and < 1–4% to DHA. Conversion is somewhat higher in younger women (estrogen modulates the relevant desaturase enzymes) and somewhat lower in men and older adults. ALA from food has independent cardiovascular benefits (the PREDIMED trial built around extra-virgin olive oil includes nut and walnut benefits in this category), but if your specific goal is to raise EPA or DHA tissue levels, ALA is not the efficient route.

EPA — the cardiovascular workhorse

Eicosapentaenoic acid is the omega-3 with the strongest cardiovascular outcomes data. The REDUCE-IT trial of icosapent ethyl (a prescription EPA ethyl ester) at 4 g/day in high-risk patients on statins reduced major adverse cardiovascular events by 25%. The follow-on STRENGTH trial of a mixed EPA+DHA carboxylic acid formulation was null — suggesting that EPA-specific formulation may matter, or that DHA dilutes the effect, or that the mineral oil placebo in REDUCE-IT inflated the effect size. The clinical guidelines remain split.

DHA — the structural omega-3

Docosahexaenoic acid is the dominant omega-3 in neuronal and retinal membranes. It's the most-studied for foetal and infant brain development, and the most-cited omega-3 for cognitive endpoints in older adults. DHA also has direct effects on triglycerides and may modestly raise LDL (which is one explanation for why mixed EPA+DHA trials underperform EPA-only on cardiovascular endpoints).

The high-dose AFib paradox. Multiple large trials (STRENGTH, OMEMI, recent meta-analyses) have found a small but consistent increase in atrial fibrillation incidence with high-dose (≥ 1 g/day combined EPA+DHA) prescription-strength omega-3 supplementation, particularly in older adults. The cardiovascular benefit-to-AFib-risk balance is favorable for high-risk groups (post-MI, very high triglycerides) but uncertain for general primary prevention. If you have known AFib, paroxysmal AFib, or are at elevated AFib risk, talk to your cardiologist before starting high-dose fish oil.

Quality matters more here than for most supplements

Omega-3s are particularly prone to oxidation. Rancid fish oil isn't just unpleasant — oxidised lipids are pro-inflammatory, the opposite of what you bought the supplement for. Look for products with:

A peroxide value (PV) and total oxidation (TOTOX) figure published, ideally TOTOX < 26.
IFOS 5-star certification (independent third-party purity and oxidation testing).
Reasonable expiration dating (12–24 months from production), stored cool.
EPA + DHA content listed as mg per serving, not just "fish oil 1000 mg" (which can be 90% non-omega-3 lipid).

Drug interactions

Anticoagulants and antiplatelets: Theoretical additive bleeding risk. Doses up to ~3 g/day are usually safe alongside warfarin / DOACs / clopidogrel under monitoring; higher doses warrant a clinician conversation.
Antihypertensives: Very small additive blood-pressure-lowering effect. Usually clinically irrelevant.
Pre-surgery: Conventional advice is to stop omega-3 supplements 7 days before elective surgery; recent reviews suggest the bleeding risk is exaggerated, but the conservative pause remains the standard.

Realistic doses

General intake (no specific deficit): 250–500 mg combined EPA+DHA per day, ideally from food (oily fish 2× per week) or a small supplement.
Pregnancy / nursing: 200–300 mg DHA per day minimum, mostly from food; algae oil for vegetarians.
Triglyceride lowering: 2–4 g per day combined EPA+DHA, often as prescription-grade.
Post-MI / high-CV-risk on statins: Discuss icosapent ethyl with your cardiologist; this is a prescription decision, not a supplement decision.

Practical rule. Most adults are fine with two servings of oily fish a week. If you don't eat fish, a 500–1000 mg combined EPA+DHA fish-oil or algae-oil supplement covers the gap. Higher doses are for specific medical indications, with clinician guidance.